Her2 targeted therapy drugs

Anti-HER2 therapies (also called HER2 inhibitors or HER2-targeted therapies) are a class of medicines used to treat all stages of HER2-positive breast cancer and certain HER2-low breast cancers.

All breast cancers are tested for HER2 status to help guide treatment. If a tumor is HER2-positive, the HER2-targeted therapy drug trastuzumab (Herceptin) is included in the chemotherapy regimen. Sometimes other drugs that target HER2 are used. Learn more about trastuzumab and other HER2-targeted therapies for early breast cancer.

What are HER2-targeted therapies? Traditional chemotherapy, radiation and surgery still play an important role in the treatment of HER2-positive cancers. These treatments often are used along with newer treatments that target HER2-positive cancer in slightly different ways. There are three main types of HER2-targeted therapies.

Purpose: Targeting HER2 with multiple HER2-directed therapies represents a promising area of treatment for HER2-positive cancers.

You usually have targeted therapy with chemotherapy or hormonal therapy drugs. The type of targeted therapy you have depends on whether the cancer is: HER2

Breast cancers that are HER2-positive have large numbers of HER2 receptors on the surface of the cancer. The HER2 targeted therapies block these

Several new drugs now have shown clinical evidence that they can be used to treat HER2-low BC as part of HER2-targeted therapy, reflecting the clearly unmet treatment needs of HER2-low BC. Researchers are exploring targeted therapies for HER2-low BC, but HER2 expression levels must be identified to guide treatment.

Anti-HER2 therapies (also called HER2 inhibitors or HER2-targeted therapies) are a class of medicines used to treat all stages of HER2-positive breast cancer.

HER2-induced breast cancer development and enhances HER2-targeted therapy The synergy scores for multiple drug combinations in HER2